Loading...
Thumbnail Image
Publication

Antigen-specific blocking of immunological synapse formation using bifunctional peptide, Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes

Manikwar, Prakash
Tejo, Bimo A.
Shinogle, Heather E.
Moore, David S.
Zimmerman, Tahl
Blanco, Francisco
Siahaan, Teruna J.
Citations
Altmetric:
Abstract
The long-term objective of this project is to utilize the I-domain protein for the alpha-subunit of LFA-1 to target drugs to lymphocytes by binding to ICAM receptors on the cell surface. The short-term goal is to provide proof-of-concept that I-domain conjugated to small molecules can still bind to and uptake by ICAM-1 on the surface of lymphocytes (i.e., Raji cells). To accomplish this goal, the I-domain protein was labeled with FITC at several lysine residues to produce the FITC-I-domain and CD spectroscopy showed that the FITC-I-domain has a secondary structure similar to that of the parent I-domain. The FITC-I-domain was taken up by Raji cells via receptor-mediated endocytosis and its uptake can be blocked by anti-I-domain mAb but not by its isotype control. Antibodies to ICAM-1 enhance the binding of I-domain to ICAM-1, suggesting it binds to ICAM-1 at different sites than the antibodies. The results in-dicate that fluorophore modification does not alter the binding and uptake properties of the I-domain protein. Thus, I-domain could be useful as a carrier of drug to target ICAM-1-expressing lymphocytes.
Description
This is the publisher's version.
Date
2011-05-01
Journal Title
Journal ISSN
Volume Title
Publisher
Ivyspring International Publisher
Research Projects
Organizational Units
Journal Issue
Keywords
Icam-1, Fitc-i-domain, Binding, Endocytosis, Raji cells
Citation
P. Manikwar, B.A. Tejo, H. Shinogle, D.S. Moore, T. Zimmerman, F.J. Blanco, and T.J. Siahaan, “Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes,” Theranostics. 1, 277–289 (2011).
DOI
Embedded videos